TNGX: Executive Chair Barbara Weber departs Tango Therapeutics, separation terms pending signature
The catalyst in focus for TNGX: Tango Therapeutics, Inc. confirmed in an August 6 SEC filing that Dr. Barbara Weber's employment as Executive Chair ended August 3, 2026, simultaneously triggering her resignation from…
Key takeaways
- Tango Therapeutics confirmed in an August 6, 2026 SEC filing that Dr. Barbara Weber's employment as Executive Chair ended August 3, 2026, ending her officer roles and board membership.
- Her severance benefits are conditional on executing and not revoking a Separation Agreement, which would pay her current base salary and COBRA reimbursements through December 31, 2026.
- Tango offered acceleration of options and RSUs that would have vested in the twelve months after August 3, 2026, with a post-termination exercise window extending to the earlier of August 3, 2027 or each grant's original expiration.
- Malte Peters, M.D., signed the 8-K as President and CEO, and the company stated Weber's departure reflected no disagreement over operations, practices, or policies.
- The Separation Agreement has not yet been filed with the SEC and will be submitted once it becomes fully effective, making that EDGAR filing the next confirmable milestone.
The catalyst in focus for TNGX: Tango Therapeutics, Inc. confirmed in an August 6 SEC filing that Dr. Barbara Weber's employment as Executive Chair ended August 3, 2026, simultaneously triggering her resignation from all officer roles and from the company's board of directors. The separation arrived under the terms of her Amended and Restated Employment Agreement, dated January 8, 2026. What to watch: the execution of a Separation Agreement that, once signed and not revoked, releases the full package of severance benefits the company has offered.
Separation package terms
The compensation Tango placed on the table is conditional. Dr. Weber must execute and refrain from revoking the Separation Agreement before any benefits flow. If she does, the company will pay severance at her current base salary through December 31, 2026, in substantially equal installments. COBRA premium reimbursements carry the same December 31 end date.
Equity and incentive elements
The equity component adds layers to the print. Tango offered acceleration of vesting on options and restricted stock units that would otherwise have vested in the twelve months following August 3, 2026. Short version: a year's worth of scheduled grants pulls forward. The post-termination exercise window on those vested options, including the accelerated tranche, extends to the earlier of August 3, 2027 or the original expiration date of each individual grant. On the cash side, she is eligible for a pro-rata share of her 2026 annual incentive payment, calculated on company and individual performance, paid no later than March 15, 2027, on the same schedule as active employees receive their annual incentive payments.
Leadership picture and what to watch next
Malte Peters, M.D., signed the 8-K as President and Chief Executive Officer, placing him at the head of the company as of the filing date. Tango Therapeutics is headquartered at 201 Brookline Ave., Suite 901, in Boston and trades on the Nasdaq Global Market under TNGX. The company stated in the filing that Dr. Weber's departure reflected no disagreement on any matter involving operations, practices, or policies.
The Separation Agreement itself has not been submitted to the SEC. Tango said the document will be filed once it becomes fully effective. That EDGAR submission is the next confirmable milestone for the tape: it will either lock in the disclosed terms or surface any revisions before they bind.